Geovax reports 2023 year-end financial results and provides business update

Progress across the pipeline in multiple clinical trials, including phase 2 program of geo-cm04s1, next-generation covid-19 vaccine, and multicenter phase 1/2 study of gedeptin ® , targeting advanced head and neck cancer

GOVX Ratings Summary

GOVX Quant Ranking